Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer
HPV and Gynecologic Cancer
Related content
HPV and Gynecologic Cancer
Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer
Gynecol Oncol.
Singh S, Guetzko M, Resnick K
doi: 10.1016/j.ygyno.
HPV and Gynecologic Cancer
Extent of Lymphadenectomy and Postoperative Major Complications Among Women with Endometrial Cancer Treated with Minimally Invasive Surgery
Am J Obstet Gynecol.
Polan RM, Rossi EC, Barber EL
doi: 10.1016/j.ajog.2018.11.1102.
HPV and Gynecologic Cancer
The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review
Gynecol Oncol.
Timmermans M, van der Hel O, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RF
doi: 10.1016/j.ygyno.2019.02.019.
HPV and Gynecologic Cancer
Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer
Am J Obstet Gynecol.
Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, Griggs JJ, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland J, O'Malley DM, Wright AA
doi: 10.1016/j.ajog.
HPV and Gynecologic Cancer
Ovarian cancer risk factor associations by primary anatomic site: the Ovarian Cancer Cohort Consortium
Cancer Epidemiol Biomarkers Prev.
Fortner RT, Rice MS, Knutsen SF, Orlich MJ, Visvanathan K, Patel AV, Gaudet MM, Tjonneland A, Kvaskoff M, Kaaks R, Trichopoulou A, Pala V, Onland-Moret NC, Gram IT, Amiano P, Idahl A, Allen NE, Weiderpass E, Poynter JN, Robien K, Giles GG, Milne RL, Setiawan VW, Merritt MA, van den Brandt PA, Zeleniuch-Jacquotte A, Arslan AA, O'Brien KM, Sandler DP, Wolk A, Håkansson N, Harris HR, Trabert B, Wentzensen N, Tworoger SS, Schouten LJ
doi: 10.1158/1055-9965.EPI-20-0354.
HPV and Gynecologic Cancer
Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers
Cancer Epidemiol Biomarkers Prev.
Glubb DM, Thompson DJ, Aben KK, Alsulimani A, Amant F, Annibali D, Attia J, Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, Bernardini MQ, Bischof K, Bjørge L, Bodelon C, Brand AH, Brenton JD, Brinton LA, Bruinsma F, Buchanan DD, Burghaus S, Bützow R, Cai H, Carney ME, Chanock SJ, Chen C, Chen X, Chen Z, Cook LS, Cunningham JM, De Vivo I, DeFazio A, Doherty JA, Dork T, du Bois A, Dunning AM, Durst M, Edwards T, Edwards RP, Ekici AB, Ewing A, Fasching PA, Ferguson S, Flanagan JM, Fostira F, Fountzilas G, Friedenreich CM, Gao B, Gaudet MM, Gawełko J, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harris HR, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Høgdall E, Høgdall CK, Holliday EG, Huntsman DG, Huzarski T, Jakubowska A, Jensen A, Jones ME, Karlan BY, Karnezis A, Kelley JL, Khusnutdinova E, Killeen JL, Kjaer SK, Klapdor R, Köbel M, Konopka B, Konstantopoulou I, Kopperud RK, Koti M, Kraft P, Kupryjanczyk J, Lambrechts D, Larson MC, Le Marchand L, Lele S, Lester J, Li AJ, Liang D, Liebrich C, Lipworth L, Lissowska J, Lu L, Lu KH, Macciotta A, Mattiello A, May T, McAlpine JN, McGuire V, McNeish IA, Menon U, Modugno F, Moysich KB, Nevanlinna H, Odunsi K, Olsson H, Orsulic S, Osorio A, Palli D, Park-Simon TW, Pearce CL, Pejovic T, Permuth JB, Podgorska A, Ramus SJ, Rebbeck TR, Riggan MJ, Risch HA, Rothstein JH, Runnebaum IB, Scott RJ, Sellers TA, Senz J, Setiawan VW, Siddiqui N, Sieh W, Spiewankiewicz B, Sutphen R, Swerdlow AJ, Szafron LM, Teo SH, Thompson PJ, Thomsen LCV, Titus L, Tone A, Tumino R, Turman C, Vanderstichele A, Velez Edwards D, Vergote I, Vierkant RA, Wang Z, Wang-Gohrke S, Webb PM, White E, Whittemore AS, Winham SJ, Wu X, Wu AH, Yannoukakos D, Spurdle AB, O'Mara TA
doi: 10.1158/1055-9965.EPI-20-0739.
HPV and Gynecologic Cancer
Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer - is interval cytoreductive surgery still needed?
Am J Obstet Gynecol.
Klein DA, Mann AK, Freeman AH, Liao CI, Kapp DS, Chan JK
doi: 10.1016/j.ajog.2019.07.050.
HPV and Gynecologic Cancer
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Lancet Oncol.
Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ, TRINOVA-3/ENGOT-ov2/GOG-3001 investigators.
doi: 10.1016/S1470-2045(19)30178-0.
COMMENTED
Uro-Oncology
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.033.